Comparative Pharmacology
Head-to-head clinical analysis: ADENOSCAN versus PRONESTYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOSCAN versus PRONESTYL.
ADENOSCAN vs PRONESTYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is a purine nucleoside that acts as a coronary vasodilator by activating A2A adenosine receptors on vascular smooth muscle, causing hyperemia. It also slows atrioventricular (AV) nodal conduction via A1 receptor activation.
Class IA antiarrhythmic; blocks sodium channels, decreases phase 0 upstroke velocity, prolongs action potential duration, and increases effective refractory period.
Intravenous administration at 140 mcg/kg/min for 6 minutes (total dose 0.84 mg/kg).
For life-threatening ventricular arrhythmias: loading dose of 100 mg IV over 5 minutes, repeated every 5 minutes as needed up to a total of 1 g. Maintenance: continuous IV infusion of 1-4 mg/min. Oral: 50 mg/kg/day in divided doses every 3-6 hours.
None Documented
None Documented
< 10 seconds (biphasic: distribution half-life < 1 second, terminal elimination half-life ~0.6-1.5 seconds). Clinically, effects are rapidly terminated due to cellular uptake and metabolism.
3-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment. Clinical context: Requires dosing every 3-4 hours to maintain therapeutic levels; sustained-release formulations allow Q6-8h dosing.
Primarily renal excretion of metabolites; <3% excreted unchanged in urine. Adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with further degradation to uric acid. <2% eliminated in feces.
Renal excretion accounts for approximately 50-60% of procainamide elimination as unchanged drug, with an additional 10-30% as the active metabolite N-acetylprocainamide (NAPA). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic